Sangamo Therapeutics, Inc SEC filings SGMOQ
Sangamo Therapeutics, Inc has 1,000 filings in SEC EDGAR's recent list, going back to Feb 5, 2013. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 14, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Feb 4, 2026 | — |
| FWP | Free writing prospectus | Feb 3, 2026 | — |
| S-8 | Employee stock plan registration | Aug 8, 2025 | — |
| 424B5 | Prospectus supplement | May 13, 2025 | — |
| FWP | Free writing prospectus | May 13, 2025 | — |
| S-8 | Employee stock plan registration | Nov 12, 2024 | — |
| S-3 | Shelf registration | Nov 12, 2024 | — |
| 424B5 | Prospectus supplement | Mar 25, 2024 | — |
| S-8 | Employee stock plan registration | Aug 8, 2023 | — |
| 424B5 | Prospectus supplement | Mar 7, 2023 | — |
| S-8 | Employee stock plan registration | Feb 23, 2023 | — |
| POS AM | Filing | Feb 23, 2023 | — |
| 424B5 | Prospectus supplement | Dec 23, 2022 | — |
| S-3ASR | Automatic shelf registration | May 5, 2021 | — |
| S-8 | Employee stock plan registration | Oct 15, 2020 | — |
| 424B5 | Prospectus supplement | Aug 6, 2020 | — |
| S-8 | Employee stock plan registration | Aug 5, 2020 | — |
| 424B5 | Prospectus supplement | Apr 4, 2019 | — |
| 424B5 | Prospectus supplement | Apr 3, 2019 | — |
| S-8 | Employee stock plan registration | Jun 11, 2018 | — |
| 424B5 | Prospectus supplement | Apr 26, 2018 | — |
| 424B5 | Prospectus supplement | Apr 24, 2018 | — |
| S-3ASR | Automatic shelf registration | Apr 24, 2018 | — |
| S-8 | Employee stock plan registration | Nov 30, 2017 | — |
| 424B5 | Prospectus supplement | Jun 22, 2017 | — |
| 424B5 | Prospectus supplement | Jun 20, 2017 | — |
| S-3/A | Filing | Jun 7, 2017 | — |
| S-3 | Shelf registration | May 26, 2017 | — |
| 424B5 | Prospectus supplement | Dec 7, 2016 | — |
| POS AM | Filing | Apr 28, 2016 | — |
| POS AM | Filing | Feb 18, 2016 | — |
| S-8 | Employee stock plan registration | Aug 6, 2015 | — |
| 424B5 | Prospectus supplement | Mar 21, 2014 | — |
| 424B5 | Prospectus supplement | Mar 19, 2014 | — |
| S-3ASR | Automatic shelf registration | Feb 25, 2014 | — |
| 424B5 | Prospectus supplement | Sep 19, 2013 | — |
| 424B5 | Prospectus supplement | Sep 17, 2013 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 28, 2013 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 28, 2013 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 28, 2013 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 28, 2013 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 28, 2013 | — |
| S-8 | Employee stock plan registration | Jun 27, 2013 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SGMOQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richmond, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1001233
- Former names
- SANGAMO BIOSCIENCES INC (until Jan 6, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.